7-Substituted Pyridyl-Naphthyridine Amides for Selective M2 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular disorders and renal disorders lack effective, potent, and safe options, particularly for conditions involving autonomic nervous system imbalances and heart failure, where M2 receptor modulation is crucial.
Innovation Solution
Development of novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides as positive allosteric modulators of the muscarinic M2 receptor, which enhance the effects of orthosteric ligands and provide a safer pharmacological profile by modulating receptor conformations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional orthosteric agonists are used to activate M2 receptors, then receptor activation and parasympathetic effects are achieved, but selectivity among muscarinic receptor subtypes is lost and toxic effects from receptor overactivation occur
Solution Approach 1:
The patent employs an allosteric modulator as an intermediary substance that indirectly influences M2 receptor activation. Rather than directly binding to the orthosteric site like conventional agonists, the allosteric modulator binds to a distinct allosteric site and modulates receptor conformation, thereby enhancing or modulating the effects of orthosteric ligands without directly activating the receptor. This intermediary mechanism provides selective M2 receptor modulation while avoiding the toxic effects associated with non-selective orthosteric agonist activation of all muscarinic receptor subtypes.
2Adaptability or versatility
If non-selective muscarinic agonists are used, then broad receptor activation occurs, but subtype specificity is lost leading to unwanted side effects
Solution Approach 1:
The patent applies the local quality principle by targeting a specific location (the allosteric site of M2 receptor) with unique properties distinct from the orthosteric site. The allosteric modulator exhibits local specificity for the M2 receptor subtype through its binding to the allosteric site, which has distinct structural characteristics compared to orthosteric sites. This local targeting approach enables selective M2 receptor modulation while sparing other muscarinic receptor subtypes, thereby reducing unwanted side effects associated with non-selective activation.
3Power
If high concentrations of agonists are used to achieve desired therapeutic effects, then receptor activation is enhanced, but self-limiting safety mechanisms are overwhelmed and toxic effects increase
Solution Approach 1:
The patent implements beforehand cushioning by utilizing the inherent self-limiting safety mechanism of allosteric modulation. Allosteric modulators naturally exhibit a ceiling effect where their ability to modulate receptor activity is limited by the availability of orthosteric ligand binding. This built-in safety mechanism acts as a cushion against toxic effects, preventing receptor overactivation even at higher concentrations. The allosteric modulator enhances therapeutic effects while the system's inherent design prevents overwhelming the safety mechanisms, maintaining a favorable pharmacological safety profile.
Data Source
AI summary
The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.